A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Study Objectives Primary:
• To determine the antitumor efficacy of single-agent Brentuximab vedotin (1.8 mg/kg
administered intravenously every 3 weeks) as measured by the overall objective response rate
in patients with relapsed or refractory primary mediastinal large B-cell lymphoma.
Secondary:
- To assess duration of tumor control, including duration of response and progression-free
survival
- To assess survival
- To assess the safety and tolerability of Brentuximab vedotin
Additional:
• To assess disease-related symptoms
Number of Planned Patients 20 patients will be enrolled in this study. Duration of the study
The study duration is 18 months for enrollment and 2 years for the follow-up.